JP2024534387A5 - - Google Patents
Info
- Publication number
- JP2024534387A5 JP2024534387A5 JP2024516579A JP2024516579A JP2024534387A5 JP 2024534387 A5 JP2024534387 A5 JP 2024534387A5 JP 2024516579 A JP2024516579 A JP 2024516579A JP 2024516579 A JP2024516579 A JP 2024516579A JP 2024534387 A5 JP2024534387 A5 JP 2024534387A5
- Authority
- JP
- Japan
- Prior art keywords
- base editor
- cells
- grnas
- mixture according
- cas protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163244219P | 2021-09-14 | 2021-09-14 | |
| US63/244,219 | 2021-09-14 | ||
| US202163278375P | 2021-11-11 | 2021-11-11 | |
| US63/278,375 | 2021-11-11 | ||
| US202263343408P | 2022-05-18 | 2022-05-18 | |
| US63/343,408 | 2022-05-18 | ||
| PCT/US2022/043557 WO2023043858A1 (en) | 2021-09-14 | 2022-09-14 | Compositions and methods for multiplex base editing in hematopoietic cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534387A JP2024534387A (ja) | 2024-09-20 |
| JP2024534387A5 true JP2024534387A5 (enExample) | 2025-09-25 |
Family
ID=85603470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516579A Pending JP2024534387A (ja) | 2021-09-14 | 2022-09-14 | 造血細胞におけるマルチプレックス塩基編集のための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240408234A1 (enExample) |
| EP (1) | EP4401744A4 (enExample) |
| JP (1) | JP2024534387A (enExample) |
| AU (1) | AU2022345079A1 (enExample) |
| CA (1) | CA3232593A1 (enExample) |
| WO (1) | WO2023043858A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| WO2024227082A1 (en) * | 2023-04-26 | 2024-10-31 | Vijay Sankaran | Base-editing perturbation screens and uses thereof |
| WO2024238565A1 (en) | 2023-05-15 | 2024-11-21 | Vor Biopharma Inc. | Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| WO2025126049A2 (en) * | 2023-12-11 | 2025-06-19 | Crispr Therapeutics Ag | Multiplex gene editing |
| WO2026077659A1 (en) * | 2024-09-17 | 2026-04-16 | Institut National de la Santé et de la Recherche Médicale | Enrichment of genetically modified hematopoietic stem cells through epigenome editing |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016337525B2 (en) * | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| AU2020338011A1 (en) * | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CLL1 modification |
| WO2021081244A1 (en) * | 2019-10-22 | 2021-04-29 | Fred Hutchinson Cancer Research Center | Base editor-mediated cd33 reduction to selectively protect therapeutic cells |
| CN116157135A (zh) * | 2020-06-03 | 2023-05-23 | 纽约市哥伦比亚大学理事会 | 使用基于crispr的碱基编辑器系统抑制谱系特异性抗原的组合物和方法 |
-
2022
- 2022-09-14 WO PCT/US2022/043557 patent/WO2023043858A1/en not_active Ceased
- 2022-09-14 CA CA3232593A patent/CA3232593A1/en active Pending
- 2022-09-14 US US18/691,720 patent/US20240408234A1/en active Pending
- 2022-09-14 EP EP22870649.5A patent/EP4401744A4/en active Pending
- 2022-09-14 AU AU2022345079A patent/AU2022345079A1/en active Pending
- 2022-09-14 JP JP2024516579A patent/JP2024534387A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024534387A5 (enExample) | ||
| Xu et al. | IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma | |
| Jayan et al. | Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2 | |
| Yin et al. | Polydopamine-based nanomedicines for efficient antiviral and secondary injury protection therapy | |
| Casey | Control of ADAR1 editing of hepatitis delta virus RNAs | |
| AU2024203377B2 (en) | Altering inflammatory states of immune cells in vivo by modulating cellular activation states | |
| Pei et al. | Differential stability of c-myc mRNAs in a cell-free system | |
| Pan et al. | The role of RNA methyltransferase METTL3 in hepatocellular carcinoma: results and perspectives | |
| Zoll et al. | The mengovirus leader protein suppresses alpha/beta interferon production by inhibition of the iron/ferritin-mediated activation of NF-κB | |
| JPH06502311A (ja) | Ｒｎａ療法を提供するためのｄｎａ構造 | |
| Xu et al. | CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity | |
| Huang et al. | Oncolytic viruses against cancer stem cells: A promising approach for gastrointestinal cancer | |
| JP2022534813A5 (enExample) | ||
| Li et al. | Prime editing: a revolutionary technology for precise treatment of genetic disorders | |
| Goldeck et al. | How RNA editing keeps an I on physiology | |
| Ma et al. | Intracellular Delivery of mRNA for Cell‐Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles | |
| JP2024542995A5 (enExample) | ||
| Bianca et al. | Role of hepatitis B virus in development of hepatocellular carcinoma: focus on covalently closed circular DNA | |
| Tabibian et al. | Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling | |
| Ouyang et al. | Delivery of Synthetic Interleukin‐22 mRNA to Hepatocytes via Lipid Nanoparticles Alleviates Liver Injury | |
| Martiniello-Wilks et al. | Transcription-targeted gene therapy for androgen-independent prostate cancer | |
| CN104010651A (zh) | 通过靶向Sirt5治疗癌症的方法 | |
| Wang et al. | Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors | |
| WO2020196737A1 (ja) | Ｂ型肝炎ウイルスタンパク質の産生を阻害する医薬組成物およびスクリーニング方法 | |
| TWI910104B (zh) | 對屬於ｙｔｈｄｃ家族之蛋白質的表現或功能之抑制劑之用途、及篩選抑制ｂ型肝炎病毒蛋白質產生的物質之方法 |